HRP20220896T1 - Liofilizirana farmaceutska formulacija i njena upotreba - Google Patents
Liofilizirana farmaceutska formulacija i njena upotreba Download PDFInfo
- Publication number
- HRP20220896T1 HRP20220896T1 HRP20220896TT HRP20220896T HRP20220896T1 HR P20220896 T1 HRP20220896 T1 HR P20220896T1 HR P20220896T T HRP20220896T T HR P20220896TT HR P20220896 T HRP20220896 T HR P20220896T HR P20220896 T1 HRP20220896 T1 HR P20220896T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation
- dihydrate
- formulation according
- pharmaceutical composition
- polysorbate
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 7
- 238000009472 formulation Methods 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims 5
- 229940074409 trehalose dihydrate Drugs 0.000 claims 5
- 108010005716 Interferon beta-1a Proteins 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 229960004461 interferon beta-1a Drugs 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 229950008882 polysorbate Drugs 0.000 claims 4
- 229920000136 polysorbate Polymers 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 239000006172 buffering agent Substances 0.000 claims 3
- 150000002016 disaccharides Chemical class 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000012931 lyophilized formulation Substances 0.000 claims 3
- 229940071643 prefilled syringe Drugs 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 238000007675 cardiac surgery Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 2
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 238000007631 vascular surgery Methods 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000006207 intravenous dosage form Substances 0.000 claims 1
- 230000002530 ischemic preconditioning effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Farmaceutska formulacija u liofiliziranom obliku, koja sadrži interferon beta-1a kao aktivni sastojak u količini od 2.0 - 15 µg u pojedinačnom intravenoznom doznom obliku, disaharide kao sredstvo za punjenje, neionski surfaktant i puferski agens, pri čemu je disaharid izabran između trehaloze dihidrata ili kombinacije trehaloze dihidrata i saharoze, i pri čemu je pH formulacije nakon rekonstitucije 6.0 - 7.5, a interferon beta-1a je rekombinantno proizveden interferon beta-1a sa biološkom aktivnošću od najmanje 150 MIU/mg.
2. Formulacija prema patentnom zahtjevu 1, pri čemu navedena formulacija dalje sadrži antioksidans.
3. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu navedeni disaharid je trehaloza dihidrat.
4. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu navedeni neionski surfaktant je polisorbat ili polietilen glikol (PEG).
5. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu navedena formulacija sadrži dinatrij fosfat dihidrat, natrij dihidrogen fosfat dihidrat, trinatrij citrat dihidrat ili njihovu kombinaciju kao pufersko sredstvo.
6. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva 2 do 5, pri čemu spomenuti antioksidans je metionin.
7. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu sadržaj preostale vlage spomenute liofilizirane formulacije nije veći od 5 mas%, poželjno u opsegu od 1-5%.
8. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je formulacija pripremljena iz vodene otopine koji sadrži
(i) rekombinantni humani interferon beta-1a kao aktivni sastojak,
(ii) trehalozu dihidrat kao sredstvo za punjenje,
(iii) polisorbat ili polietilen glikol kao surfaktant,
(iv) kombinaciju dinatrij fosfat dihidrata, natrij dihidrogen fosfat dihidrata i trinatrij citrat dihidrata kao puferski agens, i
(v) metionin kao antioksidans.
9. Formulacija prema patentnom zahtjevu 8, pri čemu vodena otopina sadrži 0.05 - 0.15 % (m/v) polisorbata ili polietilen glikola, poželjno polisorbat, i 2 - 6 % (m/v) trehaloza dihidrata.
10. Vodena farmaceutska kompozicija dobivena rekonstituiranjem liofilizirane formulacije prema bilo kojem od prethodnih patentnih zahtjeva 1 do 9.
11. Vodena farmaceutska kompozicija prema patentnom zahtjevu 10 za intravenoznu administraciju.
12. Uređaj za isporuku koji sadrži vodenu farmaceutsku kompoziciju prema patentnom zahtjevu 10.
13. Prethodno napunjena šprica koji sadrži vodenu farmaceutsku kompoziciju prema patentnom zahtjevu 10.
14. Uređaj za isporuku prema patentnom zahtjevu 12 ili prethodno napunjena šprica prema patentnom zahtjevu 13, pri čemu je unutrašnja površina uređaja za isporuku ili prethodno napunjenog šprica silikonizirana.
15. Liofilizirana formulacija iz bilo kojeg od patentnih zahtjeva 1 do 9 ili vodena farmaceutska kompozicija iz patentnog zahtjeva 10 za upotrebu u prevenciji i/ili liječenju bolesti ili poremećaja odabranih od
- vaskularno-endotelne bolesti,
- vaskularnog propuštanja kod akutnog respiratornog distresnog sindroma (ARDS) ili sindroma sustavnog upalnog odgovora (SIRS),
- ishemijsko-reperfuzijske ozlijede u vaskularnoj ili kardiokirurgiji i transplantacije organa,
- ishemijskog predkondicioniranja prije ozbiljnog vaskularnog ili kardiokirurškog zahvata i transplantacije organa,
- akutnog pankreatitisa ili akutne ozlijede bubrega,
- višestrukog zatajenja organa (MOF),
- virusnih infekcija, i
- bakterijske uplate pluća i sepse.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20165153A FI126979B (en) | 2016-02-29 | 2016-02-29 | Lyophilized pharmaceutical formulation and use thereof |
| EP17711246.3A EP3423042B1 (en) | 2016-02-29 | 2017-02-28 | A lyophilised pharmaceutical formulation and its use |
| PCT/FI2017/050128 WO2017149199A1 (en) | 2016-02-29 | 2017-02-28 | A lyophilised pharmaceutical formulation and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220896T1 true HRP20220896T1 (hr) | 2022-10-14 |
Family
ID=58347412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220896TT HRP20220896T1 (hr) | 2016-02-29 | 2017-02-28 | Liofilizirana farmaceutska formulacija i njena upotreba |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10293030B2 (hr) |
| EP (1) | EP3423042B1 (hr) |
| JP (1) | JP6869255B2 (hr) |
| KR (1) | KR20180114018A (hr) |
| CN (2) | CN107921001A (hr) |
| AU (1) | AU2017225236B2 (hr) |
| BR (1) | BR112018016545B1 (hr) |
| CA (1) | CA3011609C (hr) |
| DK (1) | DK3423042T3 (hr) |
| ES (1) | ES2922481T3 (hr) |
| FI (1) | FI126979B (hr) |
| HK (1) | HK1250147A1 (hr) |
| HR (1) | HRP20220896T1 (hr) |
| HU (1) | HUE059550T2 (hr) |
| LT (1) | LT3423042T (hr) |
| PL (1) | PL3423042T3 (hr) |
| PT (1) | PT3423042T (hr) |
| RS (1) | RS63429B1 (hr) |
| SI (1) | SI3423042T1 (hr) |
| WO (1) | WO2017149199A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1015938A2 (pt) * | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
| EP3395356B1 (en) * | 2011-02-18 | 2021-05-19 | Stemdr Inc. | Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock |
| UY38238A (es) * | 2018-05-25 | 2019-12-31 | Genzyme Corp | Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0150067A3 (en) | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US5556771A (en) | 1995-02-10 | 1996-09-17 | Gen-Probe Incorporated | Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification |
| JP4293497B2 (ja) | 1997-09-23 | 2009-07-08 | レントシュレール ビオテクノロジー ゲー・エム・ベー・ハー | インターフェロン−β液状組成物 |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| CN101664545A (zh) | 2002-07-17 | 2010-03-10 | 比奥根艾迪克Ma公司 | 使用干扰素-β治疗肾衰竭 |
| US7534423B2 (en) | 2003-03-28 | 2009-05-19 | Faron Pharmaceuticals Oy | Method for inducing an elevated level of adenosine in an individual |
| AR044302A1 (es) | 2003-05-13 | 2005-09-07 | Ares Trading Sa | Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos |
| CA2526099C (en) * | 2003-06-20 | 2013-02-05 | Ares Trading Sa | Freeze-dried fsh / lh formulations |
| JP4971160B2 (ja) * | 2004-08-12 | 2012-07-11 | シェーリング コーポレイション | 安定するｐｅｇ化インターフェロン処方物 |
| US20120269770A1 (en) * | 2010-11-22 | 2012-10-25 | Mark Brader | Stable Preserved Compositions of Interferon-Beta |
-
2016
- 2016-02-29 FI FI20165153A patent/FI126979B/en active IP Right Grant
- 2016-11-18 US US15/355,691 patent/US10293030B2/en active Active
-
2017
- 2017-02-28 CN CN201780002738.3A patent/CN107921001A/zh active Pending
- 2017-02-28 SI SI201731182T patent/SI3423042T1/sl unknown
- 2017-02-28 DK DK17711246.3T patent/DK3423042T3/da active
- 2017-02-28 PT PT177112463T patent/PT3423042T/pt unknown
- 2017-02-28 WO PCT/FI2017/050128 patent/WO2017149199A1/en active Application Filing
- 2017-02-28 LT LTEPPCT/FI2017/050128T patent/LT3423042T/lt unknown
- 2017-02-28 CN CN202211127783.0A patent/CN115364060A/zh active Pending
- 2017-02-28 KR KR1020187022141A patent/KR20180114018A/ko unknown
- 2017-02-28 PL PL17711246.3T patent/PL3423042T3/pl unknown
- 2017-02-28 HR HRP20220896TT patent/HRP20220896T1/hr unknown
- 2017-02-28 AU AU2017225236A patent/AU2017225236B2/en active Active
- 2017-02-28 EP EP17711246.3A patent/EP3423042B1/en active Active
- 2017-02-28 BR BR112018016545-0A patent/BR112018016545B1/pt active IP Right Grant
- 2017-02-28 CA CA3011609A patent/CA3011609C/en active Active
- 2017-02-28 JP JP2018545331A patent/JP6869255B2/ja active Active
- 2017-02-28 ES ES17711246T patent/ES2922481T3/es active Active
- 2017-02-28 HU HUE17711246A patent/HUE059550T2/hu unknown
- 2017-02-28 RS RS20220686A patent/RS63429B1/sr unknown
-
2018
- 2018-07-25 HK HK18109617.4A patent/HK1250147A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3423042T (lt) | 2022-08-10 |
| BR112018016545B1 (pt) | 2023-10-10 |
| US20170246254A1 (en) | 2017-08-31 |
| FI20165153A (fi) | 2017-08-30 |
| EP3423042B1 (en) | 2022-04-27 |
| JP6869255B2 (ja) | 2021-05-12 |
| KR20180114018A (ko) | 2018-10-17 |
| US10293030B2 (en) | 2019-05-21 |
| CN115364060A (zh) | 2022-11-22 |
| RS63429B1 (sr) | 2022-08-31 |
| SI3423042T1 (sl) | 2022-10-28 |
| AU2017225236A1 (en) | 2018-08-02 |
| AU2017225236B2 (en) | 2022-03-31 |
| WO2017149199A1 (en) | 2017-09-08 |
| CN107921001A (zh) | 2018-04-17 |
| ES2922481T3 (es) | 2022-09-15 |
| CA3011609A1 (en) | 2017-09-08 |
| BR112018016545A2 (pt) | 2018-12-26 |
| PT3423042T (pt) | 2022-07-25 |
| FI126979B (en) | 2017-09-15 |
| HK1250147A1 (zh) | 2018-11-30 |
| DK3423042T3 (da) | 2022-07-18 |
| PL3423042T3 (pl) | 2022-09-19 |
| JP2019513123A (ja) | 2019-05-23 |
| HUE059550T2 (hu) | 2022-11-28 |
| EP3423042A1 (en) | 2019-01-09 |
| CA3011609C (en) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11872266B2 (en) | Rapid-acting insulin compositions | |
| HRP20110801T1 (hr) | Tekući oblik fsh | |
| HRP20220896T1 (hr) | Liofilizirana farmaceutska formulacija i njena upotreba | |
| JP2016503030A5 (hr) | ||
| Murugappan et al. | Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants | |
| HRP20211520T1 (hr) | Postupci i pripravci za dostavu iduronat-2-sulfataze u središnji živčani sustav | |
| JP2016539921A5 (hr) | ||
| JP2020514412A5 (hr) | ||
| BR112018000592B1 (pt) | Composição de desbloqueio de nariz congestionado tendo atividade antiviral | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| HRP20110444T1 (hr) | Formulacije paratiroidnih hormona i njihove uporabe | |
| JP2005526084A5 (hr) | ||
| JP2017533972A5 (hr) | ||
| JP2020073566A5 (hr) | ||
| HRP20120235T1 (hr) | Formulacija tekućeg hormona rasta | |
| RU2010114007A (ru) | Применение комбинации пептидов cart в качестве терапевтического средства | |
| JP2017531682A5 (hr) | ||
| CA2934859A1 (en) | Stable compositions of peptide epoxy ketones | |
| MX2022012359A (es) | Formulacion. | |
| HRP20211197T1 (hr) | Rekombinantni glikoproteini i njihova uporaba | |
| MX2020010130A (es) | Formulacion y metodo de preparacion. | |
| KR20150074167A (ko) | Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물 | |
| HRP20211492T1 (hr) | Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja | |
| WO2015190378A1 (ja) | 安定なアダリムマブ水性製剤 |